EZH2 and prostate cancer: Notably, EZH2 and HDAC inhibitors also triggered tumor regression in an immunocompetent mouse model of AR-independent prostate cancer, PT-09, indicating that this combination remains effective in the context of an intact immune system (Figs 1J and S1E and S1 and S2 Data) [18].